NEW YORK, NY / ACCESSWIRE / October 19, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update note on Endonovo Therapeutics, Inc. (OTCQB: ENDV) and increased its target price to $0.25.
The report is available here: ENDV Update Note.
Endonovo Therapeutics, Inc. (OTCQB: ENDV, "Endonovo") is a biotechnology company focused on developing non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions in vital organs. Originally coined by GlaxoSmithKline (GSK) in 2013, electroceuticals - also called bioelectronics - are medical devices that use electrical stimulation with an aim to treat a vast range of chronic diseases. Led by Chairman and CEO Alan Collier, Endonovo was founded in 2011 and is based in Los Angeles, CA. The company is a pre-clinical stage biotechnology firm seeking to advance a pipeline of electroceutical-based treatments for chronic kidney disease, Non-Alcoholic Steatohepatitis (NASH), and vascular diseases, including ischemic cardiomyopathy and limb ischemia.
Endonovo announces positive pre-clinical results
On October 13, 2017, ENDV provided positive data regarding its pre-clinical study investigating the use of electroceuticals for the treatment and prevention of heart failure following myocardial infarction (a heart attack). In the announcement, ENDV stated that its Immunotronics™ Platform demonstrated improved cardiac function and less ventricular remodeling, in a dose-dependent manner, as evaluated using echocardiography in infarcted animals treated with its non-invasive electroceutical. The study was conducted with up to three administrations of time-varying electromagnetic field (TVEMF) technology per day for four weeks when compared to the control group. Results showed meaningful, dose-dependent impacts of Endonovo's electroceuticals on mice in an accepted model. Endonovo has released a summary of the results, which showed dose-dependent improvements in the following areas: Ejection Fraction (EF), Fractional Shortening (FS), Heart Weight-to-Body Weight Ratio (HW/BW), Left Ventricular Developed Pressure (LVDP), Left Ventricular End-Systolic Diameter (LVESD), and Interventricular Septal Dimension at Systole (IVSS).
Several potential applications for Immunotronics™ Platform
Endonovo's Immunotronics™ Platform consists of non-invasive electroceuticals that utilize time-varying electromagnetic pulses to treat vascular diseases and inflammatory conditions in vital organs. The Immunotronics™ platform seeks to accomplish this by leveraging magnetically-induced electrical pulses to reduce inflammation and promote blood vessel cell growth. The company believes its platform is differentiated in the market due to the fact that it is a non-implantable device that employs a time-varying electromagnetic field (TVEMF) approach with a slew rate and trapezoidal waveform optimized producing a cellular response and increasing stem cell growth. In addition to the results from its pre-clinical study of heart failure following Myocardial Infarction, Endonovo also announced that it is conducting pre-clinical studies of its electroceuticals on Critical Limb Ischemia, a serious form of peripheral arterial disease (PAD) characterized by severe blockage in the arteries of the lower extremities that reduces blood-flow, Non-Alcoholic Steatohepatitis (NASH) and kidney disease.
Increasing price target to $0.25
We are increasing the price target for Endonovo following the broader release of results from the pre-clinical study of its electroceuticals for heart failure following Myocardial Infarction. The results show a dose-dependent relationship with Endonovo's electroceuticals and improved cardiac function / less ventricular remodeling in a mouse model. The data should help the company advance its pipeline. We see ENDV as a speculative pre-clinical company in the biotechnology sector seeking to target a large market opportunity with its proprietary electroceutical products.
Please review important disclosures on our website at www.seethruequity.com.
About Endonovo Therapeutics, Inc.
Endonovo Therapeutics, Inc. is a leading developer of bioelectronic-applications in cell therapies and non-invasive electroceuticals. Endonovo's Immunotronics™ platform is dedicated to treating patients with life-threatening inflammatory conditions in vital organs using proprietary non-invasive electroceutical devices. The Company's non-invasive platform is based on magnetically-induced electrical field pathways that target the disruption of inflammation and cell death.
The Company's Cytotronics™ platform harnesses the bulk electrical properties of cells and tissues, namely magnetically-induced electrical field pathways to expand and enhance the therapeutic potential of cell therapies and produce next-generation biologics.
About SeeThruEquity
Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high-quality research on underfollowed small-cap and micro-cap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.
SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry's most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.
For more information visit www.seethruequity.com.
Contact:
SeeThruEquity
[email protected]
SOURCE: SeeThruEquity